Hiral Shah, a health economist, is a senior policy analyst in the Global Health programme at CGD, based in the Europe office. He focuses on providing technical expertise to the iDSI India Programme and is interested in assessing the cost-effectiveness of pharmaceutical products, cell and gene therapies, medical technologies, diagnostics, public health, environmental and economic interventions, to facilitate evidence-based policy and improve global health efficiently.
Prior to CGD, Shah was employed at the National Institute for Health and Care Excellence (NICE) within the Scientific Advice Programme. Here, he provided technical advice to pharmaceutical, medtech, cell therapy, gene therapy and diagnostic companies on their clinical development plans and economic evaluations. He also contributed to and participated in delivering educational seminars and business development for NICE Scientific Advice. Before joining NICE, Shah worked in the Zoonotic Disease Department for the Public Health Foundation of India (PHFI)based out of New Delhi. Here, he was employed as a Health Economist & Program Consultant conducting a novel economic evaluation for rabies interventions in India in collaboration with the Center for Infectious Disease Modeling and Analysis (CIDMA), Yale University. Shah has also worked with the Health Economics Team at the Warwick Clinical Trials Unit on the psychometric properties of patient reported outcomes measures. Shah has also previously worked for Bupa Health & Wellbeing as a lab technician and regional training facilitator.
Shah has a doctorate from Imperial College London. Here he was based within the prestigious MRC Unit for Global Infectious Disease Analysis in the Department for Infectious Disease Epidemiology. His doctorate focused on linking sustainability and health through exploring the impact of global agricultural production, consumption and trade on human infectious disease risks. Shah also holds an MSc in Public Health (Health Economics) from the London School of Hygiene & Tropical Medicine (LSHTM) and a BSc (Hons) in Applied Chemistry from Aston University.